文献速递MDS 与骨髓增殖性肿瘤

光学基因组图谱对骨髓增生异常综合征进行高分辨率结构变异分析,揭示具有预后和治疗意义的隐匿性异常

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance.
PubMed 文献 · Leukemia · 2022-08-01

该研究对101例连续新诊断的骨髓增生异常综合征(MDS)患者,在标准细胞遗传学和靶向NGS基础上加做光学基因组图谱(OGM)结构变异分析。OGM检出383个临床显著结构变异,其中224个(51%)为染色体显带分析(CBA)隐匿性变异,涉及34%的患者。回顾性应用OGM结果使21%和17%患者的综合细胞遗传学评分系统(CCSS)和R-IPSS风险组发生改变,并改善了预后预测。

要点

  • OGM在34%的MDS患者中检出CBA隐匿的结构变异,包括MECOM、NUP98::PRRX2、KMT2A部分串联重复等。
  • OGM使正常核型比例降低16%,检出复杂基因组(17%)和染色体碎裂(6%)。
  • 回顾性应用OGM结果改变了21%患者的CCSS和17%患者的R-IPSS风险组,并改善预后预测。

核心结论

  • OGM结构变异分析互补于NGS,可提高MDS风险分层和预后预测的准确性。

研究设计与样本

  • 单中心连续纳入101例新诊断MDS患者,均接受标准细胞遗传学和靶向NGS检测,并加做OGM结构变异分析。

主要发现

  • OGM检出383个临床显著的结构变异,其中224个(51%)为CBA隐匿性变异,见于34%的患者。
  • OGM使正常核型比例降低16%,检出复杂基因组17%和染色体碎裂6%。
  • 回顾性应用OGM结果使21%患者的CCSS和17%患者的R-IPSS风险组发生改变。
  • 多因素分析中,仅基于OGM的CCSS(而非CBA)、TP53突变和骨髓原始细胞独立预测生存。

局限性

  • OGM结果应用于CCSS和R-IPSS风险分组为回顾性分析。
  • 本研究为单中心研究。
  • 原文结论指出这是首个且最大规模报告联合结构变异分析和NGS用于MDS预后判断的研究,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chromosome banding analysis (CBA) remains the standard-of-care for structural variant (SV) assessment in MDS. Optical genome mapping (OGM) is a novel, non-sequencing-based technique for high-resolution genome-wide SV profiling (SVP). We explored the clinical value of SVP by OGM in 101 consecutive, newly diagnosed MDS patients from a single-center, who underwent standard-of-care cytogenetic and targeted NGS studies. OGM detected 383 clinically significant, recurrent and novel SVs. Of these, 224 (51%) SVs, seen across 34% of patients, were cryptic by CBA (included rearrangements involving MECOM, NUP98::PRRX2, KMT2A partial tandem duplications among others). SVP decreased the proportion of normal karyotype by 16%, identified complex genomes (17%), chromothripsis (6%) and generated informative results in both patients with insufficient metaphases. Precise gene/exon-level mapping allowed assessment of clinically relevant biomarkers (TP53 allele status, KMT2A-PTD) without additional testing. SV data was complementary to NGS. When applied in retrospect, OGM results changed the comprehensive cytogenetic scoring system (CCSS) and R-IPSS risk-groups in 21% and 17% patients respectively with an improved prediction of prognosis. By multivariate analysis, CCSS by OGM only (not CBA), TP53 mutation and BM blasts independently predicted survival. This is the first and largest study reporting the value of combined SVP and NGS for MDS prognostication.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yang H, Garcia-Manero G, Sasaki K, et al. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022. PMID: 35915143. doi:10.1038/s41375-022-01652-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。